FDA oncology roundup: drugs, imaging agents and diagnostics gain approval
Summary
The FDA approved several oncology products over a short period, including AstraZeneca’s Truqap for PTEN-deficient prostate cancer. Roche also won approval for its VENTANA PTEN companion diagnostic, which helps identify patients eligible for targeted therapy. Bayer secured approval for the low-dose MRI contrast agent Ambelvist, expanding imaging options for cancer and neurological use cases. MSD added another Keytruda combination approval in renal cell carcinoma, reinforcing its oncology portfolio.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected